DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
NYSE:DBD - US2536512021 - Common Stock
62.4 USD
-0.59 (-0.94%)
62.4 USD
0 (0%)
Taking everything into account, DBD scores 4 out of 10 in our fundamental rating. DBD was compared to 32 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has only an average score on both its financial health and profitability. DBD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
DBD had positive earnings in the past year.
DBD had a positive operating cash flow in the past year.
DBD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
1.2 Ratios
DBD's Return On Assets of -0.28% is in line compared to the rest of the industry. DBD outperforms 59.38% of its industry peers.
The Return On Equity of DBD (-1.04%) is better than 68.75% of its industry peers.
With a decent Return On Invested Capital value of 9.30%, DBD is doing good in the industry, outperforming 65.63% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DBD is significantly below the industry average of 15.13%.
The last Return On Invested Capital (9.30%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.28% | ||
| ROE | -1.04% | ||
| ROIC | 9.3% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
DBD has a better Operating Margin (7.46%) than 71.88% of its industry peers.
In the last couple of years the Operating Margin of DBD has grown nicely.
DBD has a Gross Margin of 25.30%. This is comparable to the rest of the industry: DBD outperforms 40.63% of its industry peers.
In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.46% | ||
| PM (TTM) | N/A | ||
| GM | 25.3% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
The number of shares outstanding for DBD remains at a similar level compared to 1 year ago.
Compared to 5 years ago, DBD has less shares outstanding
DBD has a better debt/assets ratio than last year.
2.2 Solvency
DBD has an Altman-Z score of 1.94. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
DBD's Altman-Z score of 1.94 is in line compared to the rest of the industry. DBD outperforms 50.00% of its industry peers.
The Debt to FCF ratio of DBD is 5.47, which is a neutral value as it means it would take DBD, 5.47 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.47, DBD is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
A Debt/Equity ratio of 0.94 indicates that DBD is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.94, DBD is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 5.47 | ||
| Altman-Z | 1.94 |
ROIC/WACC0.98
WACC9.47%
2.3 Liquidity
DBD has a Current Ratio of 1.35. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.35, DBD is in line with its industry, outperforming 43.75% of the companies in the same industry.
DBD has a Quick Ratio of 1.35. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
DBD has a Quick ratio of 0.91. This is comparable to the rest of the industry: DBD outperforms 53.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.20% over the past year.
Measured over the past years, DBD shows a very strong growth in Earnings Per Share. The EPS has been growing by 69.69% on average per year.
DBD shows a decrease in Revenue. In the last year, the revenue decreased by -0.25%.
DBD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.18% yearly.
EPS 1Y (TTM)13.2%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-18.26%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-2.61%
3.2 Future
The Earnings Per Share is expected to grow by 11.87% on average over the next years. This is quite good.
DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.83% yearly.
EPS Next Y-9.47%
EPS Next 2Y12.54%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue Next Year2.09%
Revenue Next 2Y2.41%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 22.05, DBD is valued on the expensive side.
Based on the Price/Earnings ratio, DBD is valued a bit cheaper than the industry average as 62.50% of the companies are valued more expensively.
DBD's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.17.
The Price/Forward Earnings ratio is 12.76, which indicates a correct valuation of DBD.
Based on the Price/Forward Earnings ratio, DBD is valued a bit cheaper than the industry average as 62.50% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.78. DBD is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.05 | ||
| Fwd PE | 12.76 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DBD is valued cheaply inside the industry as 96.88% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 84.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.46 | ||
| EV/EBITDA | 7.13 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.54%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
DBD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
62.4
-0.59 (-0.94%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners106.19%
Inst Owner Change-3.27%
Ins Owners1.75%
Ins Owner Change3.12%
Market Cap2.29B
Analysts82.86
Price Target77.18 (23.69%)
Short Float %2.44%
Short Ratio3.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.58%
Min EPS beat(2)-8.92%
Max EPS beat(2)1.76%
EPS beat(4)2
Avg EPS beat(4)-12.72%
Min EPS beat(4)-52.17%
Max EPS beat(4)8.44%
EPS beat(8)5
Avg EPS beat(8)24.37%
EPS beat(12)7
Avg EPS beat(12)-62.7%
EPS beat(16)7
Avg EPS beat(16)-98.89%
Revenue beat(2)0
Avg Revenue beat(2)-1.11%
Min Revenue beat(2)-1.34%
Max Revenue beat(2)-0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.4%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)1.85%
Revenue beat(8)3
Avg Revenue beat(8)-0.61%
Revenue beat(12)3
Avg Revenue beat(12)-1.61%
Revenue beat(16)3
Avg Revenue beat(16)-2.7%
PT rev (1m)4.61%
PT rev (3m)4.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.42%
EPS NY rev (3m)-1.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.05%
Revenue NY rev (3m)1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.05 | ||
| Fwd PE | 12.76 | ||
| P/S | 0.62 | ||
| P/FCF | 13.46 | ||
| P/OCF | 12.13 | ||
| P/B | 2.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.13 |
EPS(TTM)2.83
EY4.54%
EPS(NY)4.89
Fwd EY7.83%
FCF(TTM)4.64
FCFY7.43%
OCF(TTM)5.14
OCFY8.24%
SpS100.92
BVpS26.86
TBVpS-11.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.28% | ||
| ROE | -1.04% | ||
| ROCE | 11.77% | ||
| ROIC | 9.3% | ||
| ROICexc | 10.74% | ||
| ROICexgc | 34.04% | ||
| OM | 7.46% | ||
| PM (TTM) | N/A | ||
| GM | 25.3% | ||
| FCFM | 4.59% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexcg growth 3Y-11.73%
ROICexcg growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score5
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 5.47 | ||
| Debt/EBITDA | 2.27 | ||
| Cap/Depr | 14% | ||
| Cap/Sales | 0.5% | ||
| Interest Coverage | 2.11 | ||
| Cash Conversion | 46.12% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.91 | ||
| Altman-Z | 1.94 |
F-Score5
WACC9.47%
ROIC/WACC0.98
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.2%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-18.26%
EPS Next Y-9.47%
EPS Next 2Y12.54%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-2.61%
Revenue Next Year2.09%
Revenue Next 2Y2.41%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
EBIT growth 1Y39.83%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.02%
EBIT Next 3Y13.05%
EBIT Next 5YN/A
FCF growth 1Y160.17%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y173.57%
OCF growth 3Y6.68%
OCF growth 5Y26.59%